AbbVie Inc (ABBV)vsP3 Health Partners Inc (PIII)
ABBV
AbbVie Inc
$253.35
+4.20%
HEALTHCARE · Cap: $391.50B
PIII
P3 Health Partners Inc
$10.68
+9.65%
HEALTHCARE · Cap: $2.18B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 4167% more annual revenue ($62.82B vs $1.47B). ABBV leads profitability with a 5.8% profit margin vs -8.6%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
PIII
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-48.1%
Fair Value
$146.22
Current Price
$253.35
$107.13 premium
Intrinsic value data unavailable for PIII.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
3.5% revenue growth
0.0% earnings growth
Operating margin of 2.1%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.61 suggests the stock is reasonably priced for its growth.
Bull Case : PIII
The strongest argument for PIII centers on Debt/Equity.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 108.6x leaves little room for execution misses.
Bear Case : PIII
The primary concerns for PIII are Revenue Growth, EPS Growth, Operating Margin.
Key Dynamics to Monitor
ABBV profiles as a value stock while PIII is a turnaround play — different risk/reward profiles.
PIII carries more volatility with a beta of 1.60 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 34/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
P3 Health Partners Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
P3 Health Partners Inc (PIII) is a pioneering healthcare organization focused on improving care quality and reducing costs through innovative, data-driven strategies. The company utilizes telehealth technologies and advanced analytics to provide customized healthcare solutions, particularly to underserved communities, and operates a comprehensive network of primary care providers and specialists. As a leader in value-based care models, P3 partners with community organizations to address the increasing demand for efficient healthcare services. With its strong dedication to delivering high-quality, cost-effective care, PIII is strategically positioned to succeed in the rapidly changing healthcare landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?